Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Nearby (Manhasset, New York, +825 more cities)

North Shore University Hospital

AKT1 Mutation, +91 more biomarkers

Breast Carcinoma, +3 more conditions

adavosertib, +26 more drugs

immunotherapy, +1 more type

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Nearby (Manhasset, New York, +280 more cities)

North Shore University Hospital

CD22 Expression

B-Cell Acute Lymphoblastic Leukemia

allopurinol, +12 more drugs

chemotherapy, +3 more types

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Nearby (Manhasset, New York, +156 more cities)

North Shore University Hospital

CD22 Expression

B-Cell Acute Lymphoblastic Leukemia

blinatumomab, +1 more drug

chemotherapy, +1 more type

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

Nearby (Manhasset, New York, +11 more cities)

Northwell Health

Multiple Myeloma

autologous hematopoietic stem cell transplantation, +5 more drugs

cellular therapy, +4 more types

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Nearby (Lake Success, New York, +144 more cities)

Northwell Health- Monter Cancer Center ( Site 0013)

Clear Cell Renal Cell Carcinoma

belzutifan, +3 more drugs

immunotherapy, +1 more type

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

Nearby (Lake Success, New York, +226 more cities)

North Shore-Long Island Jewish Health System

EGFR Exon 19 Deletion, +1 more biomarker

Non-Squamous Non-Small Cell Lung Carcinoma

amivantamab, +3 more drugs

chemotherapy, +1 more type

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Nearby (Lake Success, New York, +523 more cities)

Northwell Health/Center for Advanced Medicine

Clear Cell Renal Cell Carcinoma

cabozantinib, +2 more drugs

immunotherapy, +1 more type

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Nearby (Lake Success, New York, +576 more cities)

Northwell Health/Center for Advanced Medicine

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

targeted therapy

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

Nearby (Lake Success, New York, +383 more cities)

Monter Cancer Center

ER Negative, +2 more biomarkers

Breast Carcinoma

atezolizumab, +4 more drugs

chemotherapy, +1 more type

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

Nearby (Lake Success, New York, +244 more cities)

Northwell Health/Center for Advanced Medicine

Bladder Urothelial Carcinoma, +4 more conditions

atezolizumab, +4 more drugs

immunotherapy

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

Nearby (Lake Success, New York, +130 more cities)

Monter Cancer Center ( Site 1080)

Bladder Urothelial Carcinoma

BCG solution, +1 more drug

immunotherapy

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

Nearby (Lake Success, New York, +199 more cities)

North Shore-Long Island Jewish Health System ( Site 0068)

Hepatocellular Carcinoma

pembrolizumab

immunotherapy